BioCentury | Apr 15, 2013
Company News

Prizm other research news

...and non-viral vector gene expression to cardiovascular tissue to treat restenosis and vascular proliferative diseases. Prizm Pharmaceuticals Inc....
BioCentury | Feb 12, 2001
Top Story

Celera sparks genomics sector

...of bacterial artificial chromosomes (BACs) and CRA applying a shotgun sequencing approach using the ABI Prizm...
BioCentury | Feb 5, 2001
Emerging Company Profile

Selective Genetics: Filling the gap

...Matrigen Inc. and Prizm Pharmaceuticals Inc. , Selective Genetics incorporates Matrigen's Gene Activated Matrix (GAM) technology and Prizm's...
BioCentury | Jun 1, 1998
Emerging Company Profile

Ciblex: The export business

...nonclassical protein export. The company was founded with technology developed at Prizm Pharmaceuticals Inc. (San Diego, Calif.). Prizm's...
BioCentury | May 11, 1998
Company News

Matrigen Inc., Prizm deal

...form Selective Genetics Inc. (San Diego, Calif.) in a stock deal valued at $30 million. Prizm...
...has $5.6 million in cash. The merger combines Matrigen's Gene Activated Matrix (GAM) technology with Prizm's...
...bone and tissue repair and regeneration. (Selective Genetics appointments, B8) Matrigen Inc., Ann Arbor, Mich. Prizm Pharmaceuticals Inc....
BioCentury | May 11, 1998
Company News

Selective Genetics management update

...Matrigen and Prizm merge, B3) Selective Genetics Inc., San Diego, Calif. Business: Gene/Cell therapy, Biomaterial/Skin/Wound Transition...
...Gene/Cell therapy, Biomaterial/Skin/Wound Transition: Steven Mendell to chairman and president, formerly president and CEO of Prizm Pharmaceuticals Inc....
BioCentury | Jan 12, 1998
Company News

Dyax, Prizm deal

...product-based royalties, but did not receive an upfront fee from Prizm. Dyax Corp., Cambridge, Mass. Prizm Pharmaceuticals Inc....
BioCentury | Jun 9, 1997
Company News

Chiron, Prizm deal

...terms and direction of further development. CHIR will sponsor research at Prizm, which will combine Prizm's...
...allow systemic delivery of gene therapy targeted to specific cells. Chiron Corp. (CHIR), Emeryville, Calif. Prizm Pharmaceuticals Inc....
BioCentury | Apr 21, 1997
Company News

Prizm other research news

...44-fold enrichment of KS-cell infection was seen for the FGF-conjugated virus compared to unconjugated virus. Prizm Pharmaceuticals Inc....
BioCentury | Feb 10, 1997
Company News

Stressgen board of directors update

...Corp. (TSE:SSB), Victoria, B.C. Business: Gene/Cell therapy, Cancer Appointed: Steven Mendell; president and CEO of Prizm Pharmaceuticals Inc. WIR...
Items per page:
1 - 10 of 16
BioCentury | Apr 15, 2013
Company News

Prizm other research news

...and non-viral vector gene expression to cardiovascular tissue to treat restenosis and vascular proliferative diseases. Prizm Pharmaceuticals Inc....
BioCentury | Feb 12, 2001
Top Story

Celera sparks genomics sector

...of bacterial artificial chromosomes (BACs) and CRA applying a shotgun sequencing approach using the ABI Prizm...
BioCentury | Feb 5, 2001
Emerging Company Profile

Selective Genetics: Filling the gap

...Matrigen Inc. and Prizm Pharmaceuticals Inc. , Selective Genetics incorporates Matrigen's Gene Activated Matrix (GAM) technology and Prizm's...
BioCentury | Jun 1, 1998
Emerging Company Profile

Ciblex: The export business

...nonclassical protein export. The company was founded with technology developed at Prizm Pharmaceuticals Inc. (San Diego, Calif.). Prizm's...
BioCentury | May 11, 1998
Company News

Matrigen Inc., Prizm deal

...form Selective Genetics Inc. (San Diego, Calif.) in a stock deal valued at $30 million. Prizm...
...has $5.6 million in cash. The merger combines Matrigen's Gene Activated Matrix (GAM) technology with Prizm's...
...bone and tissue repair and regeneration. (Selective Genetics appointments, B8) Matrigen Inc., Ann Arbor, Mich. Prizm Pharmaceuticals Inc....
BioCentury | May 11, 1998
Company News

Selective Genetics management update

...Matrigen and Prizm merge, B3) Selective Genetics Inc., San Diego, Calif. Business: Gene/Cell therapy, Biomaterial/Skin/Wound Transition...
...Gene/Cell therapy, Biomaterial/Skin/Wound Transition: Steven Mendell to chairman and president, formerly president and CEO of Prizm Pharmaceuticals Inc....
BioCentury | Jan 12, 1998
Company News

Dyax, Prizm deal

...product-based royalties, but did not receive an upfront fee from Prizm. Dyax Corp., Cambridge, Mass. Prizm Pharmaceuticals Inc....
BioCentury | Jun 9, 1997
Company News

Chiron, Prizm deal

...terms and direction of further development. CHIR will sponsor research at Prizm, which will combine Prizm's...
...allow systemic delivery of gene therapy targeted to specific cells. Chiron Corp. (CHIR), Emeryville, Calif. Prizm Pharmaceuticals Inc....
BioCentury | Apr 21, 1997
Company News

Prizm other research news

...44-fold enrichment of KS-cell infection was seen for the FGF-conjugated virus compared to unconjugated virus. Prizm Pharmaceuticals Inc....
BioCentury | Feb 10, 1997
Company News

Stressgen board of directors update

...Corp. (TSE:SSB), Victoria, B.C. Business: Gene/Cell therapy, Cancer Appointed: Steven Mendell; president and CEO of Prizm Pharmaceuticals Inc. WIR...
Items per page:
1 - 10 of 16